Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Investing.com -- Dynavax Technologies Corporation (NASDAQ: DVAX) stock soared 8% Thursday after the company announced positive topline results from its Phase 1/2 clinical trial for Z-1018, its ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax’s HEPLISAV-B revenue hit $268M in 2024, up 26% YoY, with Q4 revenue at $71M, up 39%. Analysts project Dynavax’s 2024 sales at $278.13M, with Q4 EPS at $0.04 and revenue of $72.92M. 9 ...

The company brought in $900 million selling its immune-stimulating adjuvant to others seeking Covid vaccines. Now it's turning that cash into a pipeline of potential vaccines against shingles ...

Dynavax is advancing CpG 1018 as a premier vaccine adjuvant used in clinical programs for shingles and Tdap, and in global collaborations currently focused on adjuvanted vaccines for COVID-19 ...

For Shingles, Dynavax is hoping their vaccine, compared to Shingrix, will "improve vaccine tolerability while maintaining comparable efficacy," but we will not see Phase 1/2 data until 2H 2025.

Dynavax DVAX has had a good run in the past year, with shares gaining 28% against the industry’s decline of 40.6%. Image Source: Zacks Investment Research Growth in sales of its Hepatitis B ...